Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.51 |
| ▸ | LMNA | P02545 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27584960 | 0.89 | ALDH1A1 (0.50) | ALDH1A1LMNAKDM4ETDP1HTT | |
| SCHEMBL3245678 | 0.82 | HTT (0.50) | ALDH1A1LMNAKDM4ETDP1HTT | |
| SCHEMBL5635329 | 0.82 | HTT (0.50) | ALDH1A1LMNAKDM4ETDP1HTT | |
| SCHEMBL831849 | 0.82 | ALDH1A1 (0.50) | ALDH1A1LMNAKDM4ETDP1HTT | |
| SCHEMBL854197 | 0.82 | ALDH1A1 (0.59) | ALDH1A1LMNAKDM4ETDP1HTT | |
| SCHEMBL7805532 | 0.82 | ALDH1A1 (0.59) | ALDH1A1LMNAKDM4ETDP1HTT | |
| SCHEMBL16824876 | 0.81 | ALDH1A1 (0.67) | ALDH1A1LMNAHTTGAASMN1; SMN2 | |
| SCHEMBL1811333 | 0.80 | MEN1 (0.51) | ALDH1A1LMNAKDM4ETDP1HTT | |
| SCHEMBL30310810 | 0.80 | ALDH1A1 (0.48) | ALDH1A1LMNAKDM4ETDP1HTT | |
| SCHEMBL2074082 | 0.79 | ALDH1A1 (0.52) | ALDH1A1LMNATDP1HTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221107-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| US-20070078125-A1 | Arylamine mch r1 antagonists | GLAXO GROUP LIMITED | 2007-04-05 | — | — | US | disclosed |
| US-20070078125-A1 | Arylamine mch r1 antagonists | GLAXO GROUP LIMITED | 2007-04-05 | — | — | US | disclosed |
| US-20070078125-A1 | Arylamine mch r1 antagonists | GLAXO GROUP LIMITED | 2007-04-05 | — | — | US | disclosed |
| EP-1678184-A1 | 3-(4-AMINOPHENYL)THIENOPYRIMID-4-ONE DERIVATIVES AS MCH R1 ANTAGONISTS FOR THE TREATMENT OF OBESITY, DIABETES, DEPRESSION AND ANXIETY | GLAXO GROUP LIMITED (GB) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042541-A1 | 3-(4-AMINOPHENYL) THIENOPYRIMID-4-ONE DERIVATIVES AS MCH R1 ANTAGONISTS FOR THE TREATMENT OF OBESITY, DIABETES, DEPRESSION AND ANXIETY | GLAXO GROUP LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221107-A1 | Therapeutic Agents | HTT, ACHE, GRIN2A | ALDH1A1 2368/4885LMNA 3656/4885KDM4E 2711/4885 |
| US-20070078125-A1 | Arylamine mch r1 antagonists | MCHR1, MCHR2, MC1R | ALDH1A1 736/4885LMNA 3794/4885KDM4E 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.